XRCC1基因多态性与弥漫大B细胞型非霍奇金淋巴瘤预后的关系  

Association between DNA X-ray repair cross complementary protein 1(XRCC1) polymorphisms and clinical outcome of patients with diffuse large B-cell lymphoma

作　　者：高宇[1] 魏楠[1] 李梦洁[1] 江皓[1] 

机构地区：[1]浙江医院血液科,杭州310013

出　　处：《浙江医学》2016年第12期932-935,共4页Zhejiang Medical Journal

摘　　要：目的：探讨X射线损伤交叉互补蛋白1（XRCC1）基因多态性与弥漫大B细胞型非霍奇金淋巴瘤（DLBCL）患者预后的关系。方法选取XRCC1基因3个单核苷酸多态性（SNPs）对DLBCL患者进行基因分型，并回顾分析患者预后情况，采用logistic回归分析XRCC1基因型与患者预后的关系。结果入选65例患者，平均年龄（59.7±8.0岁）；其中肿瘤相关死亡患者31例（47.7%）。XRCC1基因rs25487基因型频率在死亡组与存活组无统计学差异（P＞0.05），而等位基因频率两组间有统计学差异，其中A等位基因频率在死亡组中明显高于存活组（40.3%vs 22.1%，P＜0.05）。AA、GA、GG 3组基因型患者肿瘤相关病死率分别为75.0%（6/8）、54.2%（13/24）、36.4%（12/33）。rs25487位点A等位基因的加性模型中，每增加一个拷贝的A等位基因，风险是增加前的2.208倍（95%CI：1.039~4.694，P＜0.05）。校正年龄、性别、吸烟、B症状及和治疗方式后，A等位基因仍然显著增高患者死亡风险（OR=2.382，95%CI：1.057~5.367，P＜0.05）。结论 XRCC1基因rs25487多态性与DLBCL的预后相关。Objective To investigate the association of DNA X- ray repair cross complementary protein 1 （XRCC1） polymorphisms with the clinical outcome of patients with non- Hodgkin＇s lymphoma （NHL）. Methods Sixty five patients with diffuse large B- cel lymphoma （DLBCL）（mean age of 59.7±8.0 years） were enrol ed in the study, among whom 31 （47.7%） died from NHL during follow- up. Three single nucleotide polymorphisms （SNPs） in XRCC1 gene of patients were genotyped. Logistic regression analyses were used to compute odds ratios （ORs） and 95%confidence intervals （CIs）. Results Among three SNPs, frequency of A al ele of rs25487 was significantly higher in death group than that in survival group（40.3%vs. 22.1%, P〈0.05）. The death rates of patients with AA, GA, and GG genotype were 75.0%（6/8）, 54.2%（13/24） and 36.4%（12/33）, respectively. A al ele of rs25487 increased the risk of death in additive model with odds ratio（OR） of 2.208（95%CI：1.039~4.694, P〈0.05）. After adjusting for age, sex, smoking, B symptoms and treatment, the significance stil remained with OR =2.382 （95%CI：1.057~5.367, P〈0.05）. Conclusion rs25487 of XRCC1 gene may be correlated with outcome of DLBCL patients.

关 键 词：非霍奇金淋巴瘤 XRCC1基因 多态性 预后 

分 类 号：R733.1[医药卫生—肿瘤]